Business Segments Perspective Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 12:39:51 19/06/26 am AEST			5-day change	1st Jan Change
3.035 ^USD	+1.85%		+2.53%	+10.73%

03/06	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
03/06	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Breakdown by Business Segment (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Biological Products
Radiopharmaceutical development	-	-	1.43M	1.45M	884K
Total Assets	-	-	97.89M	341M	267M
Interest Expense	-	-	-84K	-48K	-376K
Income Tax Expense	-	-	-2.65M	-2.1M	-793K
CAPEX	-	-	-1.07M	-54.41M	-12.75M
EBT	-	-	-40.11M	-80.43M	-104M
Gross Profit	-	-	1.43M	-	-
D&A	-	-	981K	2.3M	3.24M
Operating Income	-	-	-40.94M	-90.89M	-114M
Net Income	-	-	-46.51M	-79.28M	-103M
Isotope-Based Medical Devices	10.05M	10.8M	-	-	-
Total Assets	70.42M	64.44M	-	-	-
Interest Expense	-	-	-	-	-
CAPEX	-381K	-266K	-	-	-
EBT	-3.39M	-7.27M	-	-	-
Gross Profit	5.12M	4.62M	-	-	-
D&A	210K	314K	-	-	-
Operating Income	-3.45M	-7.39M	-	-	-
Net Income	-3.39M	-7.27M	-	-	-

Geographical breakdown of sales (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
United States	10.05M	10.8M	1.43M	1.45M	884K
Total Assets	70.42M	64.44M	97.89M	341M	267M
Interest Expense	-	-	-84K	-48K	-376K
Income Tax Expense	-	-	-2.65M	-2.1M	-793K
D&A	-	-	981K	2.3M	3.24M
CAPEX	-	-	-1.07M	-54.41M	-12.75M
Gross Profit	-	-	1.43M	-	-
Net Income	-	-	-46.51M	-79.28M	-103M
EBT	-	-	-40.11M	-80.43M	-104M
Operating Income	-	-	-40.94M	-90.89M	-114M
Non - United States	5.03K	-	-	-	-